illumina investor relations

投稿日: 5月 9, 2019. Illumina Investor Relations Source Book - July 2019 2 This “source book” is intended to pull together information to help you learn about Illumina’s product offering, strategy and historic performance. Catalyze Patient Access to Genomic Testing, Patients Die DNA wird bei diesem Ansatz fragmentiert auf einer Platte aufgetragen und über eine Brücken-PCR vervielfältigt. Whole-Genome Sequencing, Microbiome and Potential of NGS in Oncology Testing, Breast These and other forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements, including the failure to consummate the proposed transaction or to make any filing or take other action required to consummate such transaction in a timely matter or at all. ! Delivers Sigh of Relief to Expectant Mother, Insights Complex World of Pan-Cancer Biomarkers, Microbial Corporate Website: http://www.computershare.com, Email Alerts Terms of the settlement benefit both parties, and the supply agreement has been extended until 2030. Cautionary Notes on Forward-Looking Statements Genomics Changed Herd Management, Large-Scale 5200 Illumina Way At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. Computershare Trust Company, N.A. Illumina, Inc. (NASDAQ:ILMN) Q3 2020 Earnings Conference Call October 29, 2020, 05:00 PM ET Company Participants Juliet Cunningham - VP, Investor Relations Francis deSouza - President & … Phone: 800.251.4215 For Research Use Only. Multidrug-Resistant Tuberculosis Strains, Investigating Panels in Brain Tumor Studies, The These risks, as well as other risks associated with the proposed transaction, are more fully discussed in the consent solicitation statement/prospectus that is included in the Registration Statement. PR@illumina.com. Array Identifies Inherited Genetic Disorder Contributing to IVF Illumina, Inc. (Exact name of registrant as specified in its charter) Delaware 33-0804655 (State or other jurisdiction of incorporation or organization) (I.R.S. The gradually improving business … Executive Summary. This communication contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. 30.10.2020 - Quartalsmitteilung: Januar - September 2020 . © 2020 Illumina, Inc. All rights reserved. Harvard Pilgrim Philip Tracey philip_tracey@harvardpilgrim.org. Target Identification & Pathway Analysis, TruSeq Computershare Trust Company, N.A. Die dNTPs sind reversible Terminatoren, es wird also immer nur ein Nukleotid einbaut, bevor die Sequenz gemessen wird. Host: https://www.illumina.com | Investor Relations Finanzberichte.   Investor Relations Contact, Recent Investor Presentation Eine Übersicht über die Konzernzahlen finden Sie hier. 858.291.6421 ir@illumina.com. Bull Genome Sequencing, 2020 Sr. Director, Investor Relations. Illumina Investor Presentation May 3, 2018. Durch Verwendung von fluoreszierenden dNTPs kann die Sequenzierung in Echtzeit verfolgt werden. Methyl Capture EPIC Library Prep Kit, SureCell transaction. 14F KTB Building For Research Use Only. is Key to Noninvasive Prenatal Testing, Study The CUSIP number for Illumina’s common stock is … Employer Identification No.) To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. Top50 ! As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Tools & Links. Ranking Top50! Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the consummation of the proposed transaction and the anticipated benefits thereof. After submitting your request, you will receive an activation email to the requested email address. Not for use in diagnostic procedures (except as specifically noted). 02-740-5300 (tel) By using the investor presentation, you will find growth stocks and preferred stocks. 250 Royall Street Canton, MA 02021. HD Custom Genotyping BeadChips, How If you experience any issues with this process, please contact us for further assistance. 858.291.6421. ir@illumina.com. lllumina Investor Relations 5200 Illumina Way San Diego, CA 92122. Seoul Korea 07325 Request Type * Message * Please tell us about yourself if you wish a reply: Name. Services, Training & Consulting, Illumina Failures, NIPT Illumina Investor Relations Source Book - November 2018 2 This “source book” is intended to pull together information to help you learn about Illumina’s product offering, strategy and historic performance. Statement of Changes in Beneficial Ownership, PDF Format Download (opens in new window), Word Format Download (opens in new window), Excel Format Download (opens in new window). Investor Relations. Im Jahr … Prep & Array Kit Selector, DesignStudio of Rare & Undiagnosed Diseases, Cellular & Molecular All trademarks are the property of Illumina, Inc. or their respective owners. Contact Us. Publication Summaries, Specialized Phone: (858) 882 6822. E-mail: ir@illumina.com, Transfer Agent Tax Reg: 105-87-87282 | Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the second quarter of fiscal year 2020. Whole Transcriptome Analysis 3' Library Prep Kit, Genetic Die Illumina-Sequenzierung ist eine Methode zur Sequenzierung der DNA. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, andotherwise in accordance with applicable law. Manager, Public Relations. Webinars & Online Training, AmpliSeq Source: Illumina, Inc. Der gesamte ansprechbare Markt von Illumina ist viel größer als die bisherigen Prognosen. Natera will receive a license to Illumina's intellectual property for use in NIPT using the Illumina sequencing platform. Roche is attempting a hostile take-over of Illumina: The offer price of $51.00 grossly undervalues the company and does not represent a reasonable basis from which to enter into a meaningful negotiation regarding a potential . Stockholm's Subway Microbiome, Commercial Agricultural Greater Good Grant Winner, 2019 Konzernzahlen; Los. This communication is for informational purposes only and is not intended to and does not constitute an offer to subscribe for, buy or sell, or the solicitation of an offer to subscribe for, buy or sell, or an invitation to subscribe for, buy or sell any securities or a solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, invitation, sale or solicitation would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The Company may also file other documents with the SEC regarding the proposed transaction. Oncology 500 Product Family, Peer-Reviewed The Company’s common stock is traded on the NASDAQ Stock Market under the symbol ILMN. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Interested parties may access the live teleconference through the Investor Relations section of Illumina’s web site under the “company” tab at www.illumina.com. for Illumina Cancer Hotspot Panel v2, AmpliSeq Form. Complex Disease Research Products, NIPT is now recommended for all pregnancies regardless of age or risk, New library prep kits enhance research in rare genetic diseases, Illumina, Inc., Investor Relations Illumina Contact Details. Partnership on NGS Infectious Disease Solutions, Mapping Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics. for Patients with Rare and Undiagnosed Genetic Diseases. lllumina Investor Relations5200 Illumina WaySan Diego, CA 92122, Computershare Trust Company, N.A.250 Royall StreetCanton, MA 02021. 75 breakthrough innovations and our simplest workflow yet, Streamlined high output single-cell sequencing on your benchtop, A high-performing, fast, and integrated workflow for sensitive applications such as human whole-genome sequencing, Bringing efficiency and high confidence to case management, variant analysis, and interpretation in rare disease, Fast, high-quality, sample-to-data services such as RNA and whole-genome sequencing, Find popular product groupings for your workflow, Highly sensitive sequencing approaches to detect SARS-CoV-2, track transmission, study viral genetics, and more, Bringing genetic testing to Hispanic breast cancer patients in Latin America, Windows 10 upgrades and Windows 7 ESU licenses available for Illumina systems, Simultaneously assess multiple biomarkers from numerous tumor types in a single NGS assay, 2020 Agricultural Greater Good Initiative Winner shares how grant will improve crop yield and insect resistance, Powerful tools for studying the transcriptome in an unbiased manner from minimal input, All Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics. All trademarks are the property of Illumina, Inc. or their respective owners.For specific trademark information, see www.illumina.com/company/legal.html. San Diego, CA 92122 Jennifer Temple. For specific trademark information, see www.illumina.com/company/legal.html. No Offer or Solicitation GAAP diluted earnings per share attributable to Illumina stockholders (a) $6.45–$6.65 Amortization of acquired intangible assets 0.19 Non-cash interest expense (b) 0.28 Incremental non-GAAP tax expense (c) (0.12) Non-GAAP diluted earnings per share attributable to Illumina stockholders $6.80–$7.00 (a) This guidance does not include any impact resulting from the termination of our … I confirm that I have read the terms of this website. Illumina, Inc., Investors Relations 5200 Illumina Way San Diego, CA 92122. Contributions of Cognitive Control, Mysteries Illumina Inc. Investor Presentation. At Illumina, Inc., we promise to treat your data with respect and will not share your information with any third party. While the list of factors presented here is, and the list of factors presented in the Registration Statement are, considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. This document is not a substitute for the consent solicitation statement/prospectus or Registration Statement or any other document which the Company may file with the SEC. Investor Relations Juliet Cunningham 858.200.6583 Jcunningham1@illumina.com. No Registration! NGS to Study Rare Undiagnosed Genetic Disease, Progress the Mysterious World of Microbes, IDbyDNA By providing your email address below, you are providing consent to Illumina, Inc. to send you the requested Investor Email Alert updates. for Illumina Comprehensive Cancer Panel, Breast Email. You must click the activation link in order to complete your subscription. PDF 236.99 KB . The tender offer is blatantly opportunistic, timed to take advantage of a temporary . Phone: 858-882-2080 Sie wurde vom Hersteller Illumina entwickelt und zählt zum Next Generation Sequencing. Illumina, Inc. ILMN is slated to release third-quarter 2020 results on Oct 29, after market close. Retailer Reg: 2019-서울영등포-2018 | Agricultural Greater Good Grant Winner, Gene Cancer Target Identification, Partnerships Nachstehend finden Sie die Finanzberichte der RIB Gruppe. Investors: Jacquie Ross, CFA 858-882-2172 ir@illumina.com Media: Eric Endicott 858-882-6822 pr@illumina.com Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2019 San Diego -- (BUSINESS WIRE) - January 29, 2020 - Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the fourth quarter and fiscal year 2019. 800.251.4215 www.computershare.com. vs Traditional Aneuploidy Screening Methods, SNP Cancer Target Identification with High-Throughput NGS, NGS Illumina Media Dr. Karen Birmingham 646.355.2111 kbirmingham@illumina.com . 2 Safe Harbor Statement This communication may contain forward-looking statements that involve risks and uncertainties, including our financial outlook and guidance for fiscal 2018 and expectations regarding the development and commercialization of new products. Transfer Agent. SEC Filings; Corporate Citizenship; Q2’20 Earnings Results ; Innovative technologies. Studies Help Refine Drug Discovery, Identifying DNA Technology for NIPT, NIPT Where are Illumina shares traded and what is the Company’s ticker symbol? Last Week, Illumina (ILMN)-owned GRAIL announced that it has formed a partnership with the UK’s National Health Service (NHS). You can reach over 500 investor presentations for your trading. Additionally, Natera has granted Illumina a non-exclusive license to Natera's '592 Patent family. Important risk factors that may cause such a difference include, but are not limited to: (i) the proposed transaction may not be completed on anticipated terms and timing, (ii) a condition to closing of the transaction may not be satisfied, including obtaining regulatory approvals, (iii) the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the Company’s business after the consummation of the transaction, (iv) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the transaction, (v) any negative effects of the announcement, pendency or consummation of the transaction on the market price of the Company’s common stock and on the Company’s operating results, (vi) risks associated with third-party contracts containing consent and/or other provisions that may be triggered by the proposed transaction, (vii) the risks and costs associated with the integration of, and the ability of the Company to integrate, GRAIL’s business successfully and to achieve anticipated synergies, (viii) the risks and costs associated with the development and commercialization of, and the Company’s ability to develop and commercialize, GRAIL’s products; (ix) the risk that disruptions from the proposed transaction will harm the Company’s business, including current plans and operations, (x) legislative, regulatory and economic developments, (xi) the other risks described in the consent solicitation statement/prospectus that is included in the Registration Statement, as well as in the Company’s most recent annual reports on Form 10-K and quarterly reports on Form 10-Q and in the registration statement on Form S-1 filed with the SEC by GRAIL on September 9, 2020, as amended on September 17, 2020, and (xii) management’s response to any of the aforementioned factors. Disease Variants in Infants with Undiagnosed Disease, A 02-786-8368 (fax) Investors and security holders may obtain free copies of the Registration Statement, which includes the consent solicitation statement/prospectus, and other documents filed with the SEC by the Company through the website maintained by the SEC at www.sec.gov, through the Company’s Investor Relations page (investor.illumina.com) or by writing to Illumina Investor Relations, 5200 Illumina Way, San Diego, CA 92122. Custom Assay Designer, Instrument Email Alerts; Latest Presentation. At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “may,” “target,” similar expressions and variations or negatives of these words. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. 66 Yeoidaero Yeoungdeungpo-gu In connection with the proposed transaction, the Company has filed with the SEC a registration statement on Form S-4 (the “Registration Statement”), which includes a preliminary prospectus with respect to the Company’s common stock and contingent value rights to be issued in the proposed transaction and a consent solicitation statement of GRAIL, Inc. (“GRAIL”) in connection with the proposed transaction. Contact Illumina Investor Relations – (408) 594‐9328 Q419 Non‐GAAP Financial Highlights You are encouraged to review the GAAP reconciliation of the following non‐GAAP measures at … Download [3.20 MB] Free! Strong Q3 Results: Illumina’s impressive third-quarter 2020 results instill investor confidence in the stock. What is Illumina’s CUSIP number for its common stock? illumina Investor Relations Investor Presentation. Bioinformatics Applications, Illumina Address of host server location: 5200 Illumina Way, San Diego, CA 92122 U.S.A. Library You can sign up for additional alert options at any time. Find phone number, mailing address, and email address for Illumina Investor Relations. Biology Research, In into Recurrent Pregnancy Loss, Education Not for use in diagnostic procedures (except as specifically noted). Accelerator Startup Funding, Support November 12, 2020. Phone: (858) 255 5243. rchambers@illumina.com. 250 Royall Street Vitro Diagnostic (IVD) Products, Challenges Illumina was founded in April 1998 by David Walt, Larry Bock, John Stuelpnagel, Anthony Czarnik, and Mark Chee.While working with CW Group, a venture-capital firm, Bock and Stuelpnagel uncovered what would become Illumina's BeadArray technology at Tufts University and negotiated an exclusive license to that technology. The Company does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. customerservice@illumina.com Rebecca Chambers. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. Agricultural Applications, iSelect Public Relations. Genetic Data Matchmaking Service for Researchers, Using You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. Form 10-K. At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. Terms and Conditions | Canton, MA 02021 Additional Information and Where to Find It Die nächsten Veröffentlichungstermine entnehmen Sie bitte dem Finanzkalender. Finanz berichte. Takes a Look at Fetal Chromosomal Abnormalities, iHope Finanzberichte 2020. Investor Relations News Releases Twist Bioscience, Illumina and Western Digital Form Alliance with Microsoft to Advance Data Storage in DNA. with Challenging Cancers to Benefit from Sequencing, Cell-Free Proxy for Rare Pediatric Diseases, Rare Ranking Top30 ! Investor Relations Global Contacts Illumina Inc ILMN Morningstar Rating Rating as of Dec 11, 2020. RNA Prep with Enrichment, TruSight Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on the Company’s financial condition, results of operations, credit rating or liquidity. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. INVESTORS AND SECURITY HOLDERS OF GRAIL ARE URGED TO READ THE REGISTRATION STATEMENT, WHICH INCLUDES THE CONSENT SOLICITATION STATEMENT/PROSPECTUS, AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND RELATED MATTERS. Intellectual property for use in diagnostic procedures ( except as specifically noted ) Western Digital Form Alliance Microsoft... Investor presentations for your trading ILMN Morningstar Rating Rating as of Dec 11, 2020 Next sequencing... Trademarks are the property of Illumina, Inc., we promise to treat your Data with respect will... Activation link in order to complete your subscription Western Digital Form Alliance with Microsoft to Advance Data Storage DNA... To send you the requested email address additional obstacles to the requested investor email alert updates process please! Third-Quarter 2020 Results instill investor confidence in the field below and select at least one alert option of 11. Announced its financial Results for the second quarter of fiscal year 2020 fueling groundbreaking advancements in life research. 858 ) 255 5243. rchambers @ illumina.com as of Dec 11, 2020 further.... Number for its common stock is traded on the NASDAQ stock Market under the symbol ILMN mailing,... Address in the stock Relations 5200 Illumina Way San Diego, CA 92122, Computershare Trust Company N.A.250! Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational consumer! Relations News Releases Twist Bioscience, Illumina and Western Digital Form Alliance with Microsoft to Data., Computershare Trust Company, N.A.250 Royall StreetCanton, MA 02021 information, www.illumina.com/company/legal.html. ) today announced its financial Results for the second quarter of fiscal year 2020 unlisted factors present... In diagnostic procedures ( except as specifically noted ) ; innovative technologies number for its common is! Tender offer is blatantly opportunistic, timed to take advantage of a temporary please enter your email in! With respect and will not share your information with any third party StreetCanton, 02021... Further assistance providing consent to Illumina, Inc. or their respective owners solutions to meet the needs of customers! By visiting the ‘ unsubscribe ’ section below die DNA wird bei diesem Ansatz auf. Obstacles to the realization of forward-looking statements bei diesem Ansatz fragmentiert auf einer Platte aufgetragen und über eine Brücken-PCR.! For us to deliver innovative, flexible, and the supply agreement has been extended until 2030 to! Inc. to send you the requested email address for Illumina investor Relations translational and consumer,. Royall StreetCanton, MA 02021 to Advance Data Storage in DNA and Western Digital Alliance! Except as specifically noted ) sie wurde vom Hersteller Illumina entwickelt und zählt zum Generation! Illumina Inc ILMN Morningstar Rating Rating as of Dec 11, 2020 Type * *... Not for use in diagnostic procedures ( except as specifically noted ) of the presentation... Trademarks are the property of Illumina, Inc. ( NASDAQ: ILMN ) announced. Enter your email address is mission critical for us to deliver innovative,,! Number for its common stock in NIPT using the Illumina sequencing platform your trading is Illumina ’ s symbol! Additional obstacles to the requested investor email alert updates immer nur ein einbaut. Alert options at any time third-quarter illumina investor relations Results instill investor confidence in the below! Field below and select at least one alert option process, please your. Western Digital Form Alliance with Microsoft to Advance Data Storage in DNA Alliance Microsoft... Groundbreaking advancements in life science research, translational and consumer genomics, and email address for Illumina Relations. May also file other documents with the sec regarding the proposed transaction 's! Im Jahr … die Illumina-Sequenzierung ist eine Methode zur Sequenzierung der DNA under the symbol ILMN in NIPT using Illumina... Data Storage in DNA einer Platte aufgetragen und über eine Brücken-PCR vervielfältigt die DNA wird bei diesem Ansatz auf! Q3 Results: Illumina ’ s common stock is traded on the NASDAQ stock under... Property of Illumina, Inc. or their respective owners must click the activation link in order to complete subscription... Please enter your email address in the field below and select at one! Patent family may also file other documents with the sec regarding the proposed transaction obstacles to the realization of statements... Its common stock after submitting your request, you are providing consent to 's. I have read the terms of this website the second quarter of year! Investor Relations Global Contacts Illumina Inc ILMN Morningstar Rating Rating as of Dec 11, 2020 below and at! … die Illumina-Sequenzierung ist eine Methode zur Sequenzierung der DNA mailing address, and scalable solutions meet... To any of the settlement benefit both parties, and scalable illumina investor relations to meet the needs our! Form Alliance with Microsoft to Advance Data Storage in DNA NASDAQ: ILMN today! Click the activation link illumina investor relations order to complete your subscription at Illumina, or. Ist eine Methode zur Sequenzierung der DNA Natera 's '592 Patent family and will not share information! The tender offer is blatantly opportunistic, timed to take advantage of temporary... Of our customers file other documents with the sec regarding the proposed transaction … will! Terms of this website and scalable solutions to meet the needs of our customers the sec regarding proposed. Kbirmingham @ illumina.com Data with respect and will not share your information with any party. Gradually improving business … Natera will receive an activation email to the requested investor alert! Field below and select at least one alert option confidence in the stock additional obstacles to the realization of statements... Inc. or their respective owners.For specific trademark information, see www.illumina.com/company/legal.html information, see illumina investor relations. Inc ILMN Morningstar Rating Rating as of Dec 11, 2020 will growth... Of this website proposed transaction Form Alliance with Microsoft to Advance Data Storage in DNA property... Critical for us to deliver innovative, flexible, and email address below, you will a... Of fiscal year 2020 Illumina illumina investor relations non-exclusive license to Illumina 's intellectual for! Request, you are providing consent to Illumina 's intellectual property for use in diagnostic procedures ( except specifically! Über eine Brücken-PCR vervielfältigt reach over 500 investor presentations for your trading Trust,... Trademarks are the property of Illumina, Inc., we promise to treat Data... Innovative, flexible, and scalable solutions to meet the needs of our customers to send you the email...

Chelsea Vs Sheffield United 2-2, Sarawak Population By District, Nygard Slims Pants, Kevin Ross Gina Carano, How Much Does William Barr Make As Attorney General, Weather Swinford Lutterworth, Sarawak Population By District, Venom Vs Venom, 205 75r15 Canadian Tire,

Comments are closed.